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SINCE the introduction of cyclosporine (CsA)-steroid therapy for our liver trans-
plant recipients in March 1980, the survival 
rates have increased significantly as shown in 
Fig 1. The effective and relatively safe immu-
nosuppression provided by CsA is undoubt-
edly the most important factor in the 
improved success rate. l 
k~Dphrotoxicity is a troublesome side effect 
of CsA. The distinction between nephrotoxic-
ity and rejection poses a major diagnostic 
dilemma in renal transplantation,2 but not 
after extrarenal organ transplantation. How-
ever, end-stage liver diseases often predispose 
to renal dysfunction, and extensive surgical 
intervention also can cause acute renal 
impairment. Thus, a different kind of "arti-
~ fact" may exist in the assessment of drug J; 
:1, ne~~~~o:~~i~r~er transplantation provides a 
I reasonable model to study some aspects of the 
t:nephrotoxicity of CsA. In this report, acute 
:~: and chronic renal dysfunction among our liver 
4 transplant recipients will be described. 
........ "-~ 
esA-STEROID THERAPY 
A brief description of our management 
~D practices is in order. If there are several hours 
i.'·,.... with which to prepare a recipient for liver 
I transplantation, an initial loading dose Of 17.5 
4t mg/kg of esA is administered orally.;If the 
1, oral loading is possible, CsA is usually not 
;(,; given again until the operation is completed at 
D~D which time the venous.route is used. If there is 
:+ 
d. not enough time before surgery for oral load-
~i ing, all therapy is withheld until 2 mg/kg of 
intravenous (IV) CsA is administered over a 
K~I" period of two to three hours after revasculari-
, zation of the graft. If the recipient becomes 
hemodynamically stable and is producing an 
adequate amount of urine, the IV dose is 
repeated every eight to 12 hours in the early 
postoperative period. The IV medication is 
continued, even after the resumption of oral 
intake. 
Although oral CsA (17.5 mg/kg/d in two 
divided doses) is administered as soon as can 
be tolerated postoperatively, the intestinal 
absorption of the drug is usually poor for a few 
weeks after liver transplantation. Therefore, 
during the early postoperative period, CsA is 
administered IV as well as orally (double-
route therapy) to maintain adequate trough 
levels of the drug (usually 800 ± 200 ng/mL 
of whole blood measured by radioimmunoas-
say [RIA]). When an adequate blood level of 
the drug can be maintained by the double-
route therapy, the IV doses of CsA are grad-
ually tapered and discontinued at the same 
time that oral doses are increased accord-
ingly. 
Often, oral doses > 17.5 mg/kg/ dare 
required during the early posttransplant 
period to maintain an adequate blood level. 
However, if renal dysfunction exists, the dose 
of CsA is reduced and the whole blood trough 
levels are allowed to drift to as low or lower 
than 300 ng/mL. Then, additional doses of 
steroids may be required to prevent the graft 
rejection. More recently, monoclonal anti-
body therapy has been used. With the 
improvement of renal function, the dose of 
CsA is gradually increased to reach a thera-
peutic drug level consistent in that patient 
with satisfactory renal function. 
When satisfactory and stable graft function 
is obtained (usually a month or two after 
From the Department of Surgery, University of Pitts-
burgh Health Center. Pittsburgh. 
Supported by a research grant from the Veterans 
Administration and by project grant No. AM·29961 
from the National Institutes of Health. 
Address reprint requests to Dr Shunzaburo Iwatsuki, 
Department of Surgery, 3601 Fifth Ave. Room 103. Folk 
Clinic, Pittsburgh, PA 152 I 3. 
© 1985 by Grune & Stratton. Inc. 
0041-/345/85//704-1021 $03.00/0 
Transplantation Proceedings, Vol XVII, No 4, Suppl 1 (August), 1985 191 
192 
PERCENT SURVIVAL 
1007...,,---------------·-----, 
90 
70 
60 
50 6;, 
4,0 b 
"B·,,"'0·····e-,···-e··. __ e-.... -e. ____ e-. ___ -e _____ e .... -€l 
30 
20 
IWATSUKI ET AL 
~ 
10 l 
lD---KKKKKKKKt-KK--D--D---D-D--D--D--D----D--D-~~~--D--D~ l 
o 2 3 4, 5 6 7 8 9 10 Fig 1. Actuarial survival after liver I 
YEARS transplantation, '. 
transplantation), long-term dose adjustments Immediately before liver transplantation, .' 
are directed by side effects of CsA, such as three adult and two pediatric patients had 
I,"", .... ;.. 
nephrotoxicity, tremor, gum hyperplasia, hir- abnormal renal functions (BUN level> 50 r 
.::i 
sutism, and hypertension, rather than relying mg/IOO mL and/or serum creatinine> 2 
solely on blood concentrations of the drug. / mg/100 mL). One of the adult and one of the 
Corticosteroids are used in combination pediatric patients were receiving hemodialysis 
with CsA not only as rejection therapy, but (Table 1). 
~i 
also as a maintenance immunosuppressive Before the introduction of CsA, acute renal 
therapy. Steroid therapy is begun immedi- dysfunction postoperatively was often ob-
ately before the revascularization of the graft served. Massive transfusion during surgery, 
with a bolus of IV methylprednisolone. After failure of prompt graft function, and infec· 
the operation, a five-day burst of prednisone tious complications were predisposing factors. 
or methylprednisolone is started at 200 mg/d Without these complications, severe renal 
in adults. The dose is reduced by daily decre- dysfunction was uncommon with conventional 
inents of 40 mg to a maintenance dose of 20 triple-drug immunosuppressive therapy (aza-
mg/ d for adults. In children, smaller doses of thioprine, steroids, and antilymphocyte globu-
steroids are used. The maintenance dose of lin [ALG]). In order to eliminate the transient 
prednisone at one month is 15 to 20 mg/d for and mild renal dysfunction inherent in liver 
adults and 5 to 15 mg/d for children. Further transplant surgery, acute renal dysfunction 
reductions of prednisone depend on graft postoperatively is defined as follows in this 
function. report: for adult recipients, BUN level of 100 
ACUTE RENAL DYSFUNCTION DURING A 
ONE-YEAR SAMPLE 
From Jan 1 to Dec 31, 1984, 135 patients 
with various end-stage liver diseases received 
their first liver grafts while receiving CsA-
steroid therapy at the University Health Cen-
ter of Pittsburgh (Pittsburgh). Seventy-one of 
the 135 patients were adults (18 years old or 
older), and the remaining 64 patients were 
children (under 18 years old). As of March 1, 
1985,58 (82%) of the 71 adults and 57 (89%) 
of the 64 children are alive. 
mg/ 1 00 mL or greater and/or serum creati-
nine level of 5 mg/ I 00 mL or greater; and for 
Table 1. Incidence of Renal Dysfunction Before and 
After Liver Transplantation 
Abnormal Renal Acute Renal 
Function Before DysfunctIon After 
liver Transplant Liver Transplant 
(%) (%) 
Adults 
(<:o18y,) 3/7114) 15/71 (21) 
Children 
«18 yr) 2/64 (3) 14/64 (22) 
Total 5/135 (4) 29/135 (21) 
.l I·'·.····!· 
" I 
'. ' t· , 
. '. 
CsA NEPHROTOXICITY IN LIVER GRAFTS 
pediatric recipients, BUN level of 70 mg/mL 
or greater and/or serum creatinine level of 3 
mg/mL or greater .during the first three 
months after liver transplantation. 
There were 15 (21 %) of the 71 adult and 14 
(22%) of the 64 pediatric liver recipients who 
developed severe acute renal dysfunction as 
just defined above (Table 1). In response to 
the complication, esA was administered in 
quantities far less than the usual early mainte-
nance doses, and the trough levels were kept 
<500 ng/mL of whole blood measured by 
RIA. 
Among the 15 adult recipients, only three 
had abnormal renal function before trans-
plantation and one was already receiving 
hemodialysis. Five of the 15 adult recipients 
required hemodialysis after liver transplanta-
tion, and all died within three months. These 
five patients had very poor liver graft func-
tion. Four of them received second grafts, and 
r, two of the four received the third grafts within 
~ two months. ~I 
'* Among the remaining ten adult patients (of 
!t\ the 15 with renal failure), only two had abnor-~ 
< mal kidney function before transplantation I and both regained near-normal renal function 
~I after liver transplantation. They are alive and 
.,¥, I ~egl in the fourth and 12th months. q~K<?I~her I, eIght patients had normal renal function 
~KK before transplantation. Five of them died in ~ three months with liver failure and infectious jl. 
Jij complications. In the end, ten (67%) of the 15 ~K patients who developed severe renal dysfunc-I'" tion postoperatively died despite the drastic 
....• decrease of or temporary withdrawal o~CsAK , 
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Liver failure and infectious complications 
were almost always present. 
Among the 14 pediatric recipients with 
postoperative renal dysfunction, only two had 
abnormal renal function before transplanta-
tion. One patient was already receiving acute 
hemodialysis and the other was receiving 
chronic dialysis because of renal cystic dis-
ease. For the latter patient, both kidney and 
liver were transplanted from the same donor. 
The patient with acute preoperative renal 
failure (from Wilson's disease) was dialyzed 
four times after liver transplantation. The 
liver-kidney recipient did not need dialysis. 
Both patients are living and well with good 
renal functions in the fourth and sixth 
months. 
The remaining 12 children developed 
severe renal dysfunction after transplantatio[' 
Although all 12 patients had a BUN level of 
70 mg/ 1 00 mL or greater, only four of then~ 
had a serum creatinine level of 2 mg/100 mL 
or greater. None of the 12 required hemodial-
ysis after transplant and only three have died 
as of March 1, 1985. The three patients who 
died had very poor liver function, and two of 
them had severe infectious complications as 
well. The other nine patients are all alive and 
well with good renal as well as hepatic func-
tion. 
Thus, severe acute renal dysfunction after 
liver transplantation was always associated 
with preexisting renal failure, difficult sur-
gery, poor liver function, and/or infectious 
complications. In the absence of these prob-
lems, nephrotoxicity of CsA did not cause 
Table 2. Renal Function and CsA Dose After Liver Transplantation in Adults and Children 
Creatinine mg % 
CsA mg/kg/d 
Pediatric (age < 18 yr) 
BUN mg/l00 mL 
Creatinine mg % 
CsA mg/kg/d 
Before 
Transplant 2mo 6mo lyr 2 yr 3yr 4yr 
17.7 ± 17.0 37.0 ± 21.6 40.5 ± 43.9 37.7 ± 31.1 33.7 ± 12.9 26.1 ± 8.5 20.8 ± 5.1 
1.1±O.8 1.5±0.6 1.7±O.6 1.7±0.6 1.8±0.6 1.5±0.3 1.3±0.4 
13.9 ± 7.4 8.2 ± 3.8 6.1 ± 2.0 5.0 ± 1.9 4.9 ± 1.9 6.2 ± 2.7 
18.4 ± 24.7 24.8 ± 16.3 24.2 ± 11.2 20.8 ± 9.5 
0.8 ± 1.8 0.5 ± 0.3 0.7 ± 0.4 0.6 ± 0.4 
23.3 ± 14.7 17.0 ± 9.2 14.6 ± 8.9 
22.2 ± 9.1 
0.7 ± 0.3 
9.3 ± 2.3 
25.9 ± 10.2 21.5 ± 9.2 
0.6 ± 0.4 0.8 ± 0.2 
9.0 ± 6.3 8.7 ± 1.8 
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significant morbidity when the dose was 
adjusted properly during the first three 
months after liver transplantation. 
CHRONIC RENAL DYSFUNCTION IN 
CHRONIC SURVIVORS 
From March 1980 to February 1984, 178 
patients with various end-stage liver diseases 
received the first liver grafts while receiving 
CsA-steroid therapy. One hundred thirty-six 
(76%) of the 178 recipients survived one to 
five years after transplant as of March 1985. 
Sixty-nine of the 136 one-year survivors 
were adults; and remaining 57 were children. 
BUN and serum creatinine levels and the oral 
doses of CsA (mg/kg/d) were analyzed 
before transplantation; at 2, 6, and 12 months; 
and yearly up to five years to study chronic 
nephrotoxicity of CsA when the doses were 
adjusted by close monitoring of renal function 
as mentioned earlier. The mean values with 
SDs are shown in Table 2. 
Among the 69 adult one-year survivors, 
there were five patients who had abnormal 
renal function (serum creatinine level 2 mg/ 
100 mL or greater) before transplantation; 
none were on hemodialysis. In three of these 
five patients, renal function improved after 
liver transplantation to serum creatinine levels 
<2 mg/IOO mL, but in two, the improvement 
was limited to serum creatinine levels of 2.5 
mg/IOO mL and 3.5 mg/IOO mL under CsA-
steroid therapy. 
Sixty-five of the 69 adult patients had nor-
mal or near normal renal functions (serum 
creatinine level <2 mg/ 1 00 mL) before trans-
plantation. Only one of the 65 patients devel-
oped severe renal failure after transplantation 
that necessitated hemodialysis for a month. 
This patient had been an insulin-dependent 
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diabetic for 15 years before transplantation. 
He received reduced doses of CsA for the first 
two days and for two weeks in the second 
month after transplantation. During the other 
postoperative times, he was given azathio-
prine-steroid therapy because of renal failure. 
The patient's renal function slowly deterio-
rated on azathioprine-prednisone therapy but 
did no~ require hemodialysis other than dur-
ing th~ immediate postoperative period. He 
died of.' a myocardial infarction after one year. "-
The rest of adult survivors did not develop t 
chronic progressive renal dysfunction under .1·.'::. 
CsA-steroid therapy during one to five years. 
The numbers of adult one-year survivors 
who had abnormal renal functions (BUN level 
>501>m.g%, creatinine level >2 mg/IOO mL)'f 
before and after liver transplantation are sum-
marized in Table 3. The incidence of renal! 
dysfunction increased after transplantation} 
under CsA-steroid therapy. However, it grad- , 
ually decreased with reduction of esA dosage 'I 
during the observation of up to five years. 
Among the 57 pediatric one-year survivors, I 
seven children had abnormal renal functions I 
(creatinine level >1 mg/IOO mL) before l 
transplantation, but only one of them was . 
receiving hemodialysis. None required hemo- I 
dialysis after transplant. In all of these seven 1 
children, renal function improved after liver 
transplantation under CsA-prednisone thera-
py. In the remaining 50 children, the serum 
creatinine level was < I mg/ I 00 mL before 
transplant. None of the 57 children developed 
chronic, progressive renal dysfunction while 
receiving CsA-steroid therapy during one to 
five years. 
The numbers of pediatric one-year survi-
vors who had abnormal (BUN level >30 
mg/ I 00 mL, creatinine level > 1.0 mg/ 1 00 
Table 3. Incidence of Renal Dysfunction Among 69 Adult One-Year Survivors After liver Transplentation With 
CsA-Steroid Therapy 
Before 
Transplant 2ma 6ma 1 yr 2 yr 3 yr 4 yr 5 yr 
Serum creatinine"" 1 mgt' 00 ml 5/69 19/69 18/69 18/69 8/34 2/17 1/6 0/1 
% 7 28 26 26 24 12 17 0 
BUN;;,: 30 mg/dL 3/69 12/69 8/69 9/69 3/34 0/10 0/6 0/1 
% 4 17 12 13 9 0 0 0 
lK~: 
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Table 4. Incidence of Renal Dysfunction Among 57 Pediatric One-Year Survivors After Liver Transplantation With 
CsA-Steroid Therapy 
Before 
Transplant 2mo 6 me 1yr 2 yr 3 yr 4yr 
Serum creatinine ~ 1 mg/l00 mL 7/57 4/57 12/57 8/57 2/28 1/11 0/2 
% 12 7 21 14 7 9 0 
BUN ~ 30 mg/dL 6/57 17/57 16/57 8/57 3/28 1/11 0/2 
% 11 
mL) before and after liver transplantation are 
summarized in Table 4. The incidence of renal 
dysfunction increased after transplant under 
CsA-steroid therapy, but it gradually de-
creased with reduction of CsA dosage during 
the observation of up to five years. 
DISCUSSION 
30 28 14 11 9 0 
major causes of renal impairment. The dose of 
CsA must be carefully adjusted to avoid neph-
rotoxicity. Daily monitoring of the drug level 
is helpful in adjusting the dose particularly 
during the immediate and early posttrans-
plant period. 
Recently, chronic and irreversible renal 
damages were reported both in heart8 and 
Acute and reversible nephrotoxicity of CsA kidney9 transplantation under long-term CsA 
was recognized Soon after the introduction of therapy. Histologic changes characterized by 
this effective and safe immunosuppressive tubulointerstitial fibrosis were thought to be 
agent in clinical organ transplantation.3- 7 progressive. In the present clinical study of i Severe renal dysfunction during the early chronic renal dysfunction in 136 liver trans-
~ postoperative period of liver transplantation is plants receiving CsA therapy for one to five I' an ominous prognostic sign often accompa- years, we could neither find an example of 
',0 nied by unstable hemodynamics, poor liver chronic, progressive renal dysfunction, nor 
~ 
" function, and/or infectious complications. In could we find any evidence of increasing inci-i our study of acute renal dysfunction, 13 (45%) dence of chronic, renal impairment (Tables 2 t of the 29 recipients who had severe renal through 4). Although recipients of different ~Df failure died within three months after trans- organs were studied, the lack of chronic, pro-f plantation.' ... ~ .... gressive renal dysfunction in our liver recip-I .. DKDKF~ .... ' CsA is an additional cause of acute renal ients was probably due to our policy of dose " dysfunction in liver transplantation, in which adjustment to avoid nephrotoxicity rather 
" hemodynamic instability, massive operative than to maintain any specific trough level of i ;nt",ent;on, and "ry poo, H", funct;~::::ob:~:: CsA. 
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